Galectin Therapeutics (GALT) Misses Q2 EPS by 1c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Jefferies names five top tech picks after August reporting season
• QNB Corp. sells $254M in securities in portfolio repositioning